AstraZeneca reported positive Phase 3 results for gefurulimab in myasthenia gravis, achieving all primary and secondary endpoints and demonstrating meaningful clinical improvement. The company also revealed a significant $50 billion commitment to U.S. manufacturing and R&D, including a new Virginia facility to produce small molecules and peptides, underpinning growth ambitions. Additionally, updated overall survival data from the Flaura2 study showed improved survival for Tagrisso combined with chemotherapy in EGFR-mutated lung cancer, bolstering AstraZeneca’s competitive position in oncology.